Consolidated Statements of Stockholders (Deficit) Equity - USD ($) $ in Thousands	Common Stock Series B Preferred	Common Stock Series A Preferred Stock [Member]	Common Stock	APIC Series B Preferred	APIC Series A Preferred Stock [Member]	APIC	Accumulated Deficit Series B Preferred	Accumulated Deficit Series A Preferred Stock [Member]	Accumulated Deficit	Non-Controlling InterestAccumulated Non-Controlling Stockholders' Series B Preferred	Non-Controlling InterestAccumulated Non-Controlling Stockholders' Series A Preferred Stock [Member]	Non-Controlling InterestAccumulated Non-Controlling Stockholders'	Preferred Stock [Member] Series B Preferred	Preferred Stock [Member] Series A Preferred Stock [Member]	Series B Preferred	Series A Preferred Stock [Member]	Total
Stock-based compensation			$ 0			$ 350			$ 0			$ 0	$ 0				$ 350
Stock issued under "at-the-market" offering			$ 9			3,350			0			0	0				3,359
Stock issued under "at-the-market" offering (in shares)			9,256,535
Series A Preferred Stock Dividends			$ 0			0			254			0	0				254
Issuance of SYN Biomics Stock			0			0			0			178	0				178
Effect of Warrant exercise price adjustment			0			880			(880)			0	0				0
Conversion of Series B Preferred Stock to Common			$ 3			3,661			(1,380)			0	$ (2,284)				0
Conversion of Series B Preferred Stock to Common (in shares)			3,186,960										(3,665)
Net Loss			$ 0			0			(10,043)			(73)	$ 0				(10,116)
Non-controlling interest																	(73)
Balance at Dec. 31, 2020			29			240,821			(248,094)			(2,773)	2,477				(7,540)
Balance at Dec. 31, 2019			$ 17			232,580			(235,537)			(2,878)	$ 4,761				(1,057)
Balance (in shares) at Dec. 31, 2020			29,249,925										3,973
Balance (in shares) at Dec. 31, 2019			16,806,430										7,638
Stock-based compensation			$ 0			416			0			0	$ 0				416
Stock issued under "at-the-market" offering			$ 79			65,881			0			0	0				65,960
Stock issued under "at-the-market" offering (in shares)			78,685,315
Series A Preferred Stock Dividends			$ 0			0			24			0	0				24
Conversion of Series B Preferred Stock to Common	$ 3			$ 3,971			$ (1,497)			$ 0			$ (2,477)		$ 0
Conversion of Series B Preferred Stock to Common (in shares)	3,454,783												(3,973)
Net Loss			0			0			(14,267)			(1)	$ 0				(14,268)
Reversal of noncontrolling interest due to return of Syn Biomics shares			0			(2,774)			0			2,774	0				0
Warrants Exercised			$ 12			8,030			0			0	0				8,042
Warrants Exercised (In shares)			11,655,747
Effect of Series A Preferred Stock price adjustment			$ 0			7,402			(7,402)			0	0				0
Conversion of Series A Preferred Stock to Common		$ 9			$ 12,813			$ 0			$ 0			$ 0		$ 12,822
Conversion of Series A Preferred Stock to Common (in shares)		8,996,768
Non-controlling interest																	(1)
Balance at Dec. 31, 2021			132			336,560			(271,284)			0	0				65,408
Balance at Dec. 31, 2020			$ 29			$ 240,821			$ (248,094)			$ (2,773)	$ 2,477				$ (7,540)
Balance (in shares) at Dec. 31, 2021			132,042,538
Balance (in shares) at Dec. 31, 2020			29,249,925										3,973